Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
Researchers are evaluating zongertinib, an oral HER2-targeted drug, to see if it can improve outcomes compared to standard adjuvant treatments in adults with completely removed Stage II to IIIB non-small cell lung cancer NSCLC that has activating HER2 tyrosine kinase domain mutations. This Phase 3, global, randomized, open-label study includes participants who have had surgery with curative intent and received perioperative systemic therapy such as neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomly assigned to one of two groups one group takes zongertinib daily by mouth for up to three years, while the other group follows standard care, which may include approved adjuvant immunotherapy or observation based on local guidelines and patient condition. This comparison aims to determine if zongertinib can extend disease-free survival. Safety, overall survival, tolerability, and patient-reported outcomes are also monitored during the study. During the study, participants undergo regular evaluations including disease assessments by investigators for up to 8 years and 5 months to measure disease-free survival and overall survival. Safety is tracked by recording adverse events, especially those of grade 3 or higher, from treatment start through up to three years or tumor recurrence. Participants provide tumor tissue samples for HER2 status confirmation, and their overall health and organ functions are monitored. The entire study lasts several years, including follow-up to assess long-term outcomes.
Actively Recruiting
This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.